2024
Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaOverall survivalCox proportional hazards multivariate modelPresence of visceral metastasesChi-square test/Fisher's exact testIS groupPractice patternsPredictors of OSKaplan-Meier methodImpact practice patternsLog-rank testMedicare groupPrivate insuranceMulti-institutional studyANOVA/Kruskal-Wallis testVisceral metastasesInsurance payer statusNeoadjuvant chemotherapyNCI-designated comprehensive cancer centerSystemic therapyUrothelial carcinomaMedian ageBaseline characteristicsExact testClinical trial participation
2022
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
Zengin Z, Henderson N, Park J, Ali A, Hwang C, Barata P, Bilen M, Graham L, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts). Journal Of Clinical Oncology 2022, 40: 138-138. DOI: 10.1200/jco.2022.40.6_suppl.138.Peer-Reviewed Original ResearchAR alterationsAR mutationsGenomic testingAdvanced prostate cancer patientsAndrogen receptor alterationsKaplan-Meier methodLog-rank testProstate cancer patientsAlteration statusMedian TTPPSA declineCastration resistancePSA responseMedian ageAR amplificationDocetaxel exposureReceptor alterationsStratified patientsTestosterone suppressionShorter TTPCancer patientsTreatment outcomesAbirateroneCastration statusDomain mutations